CD20-specific-T-cells

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD20-specific-T-cells
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Active IndicationsN/A
Inactive IndicationsWaldenstrom MacroglobulinemiaLymphoma, B-CellLymphoma, Non-Hodgkin +[6] 

Other Information

ATC CodeN/A
Related LinksN/A